Miami Cancer Institute Immunotherapies Evaluation - Day 2

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree

	5	4	3	2	1
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1

How confident are you in your ability to: *

5 = High level of confidence 4 = Moderately high level of confidence 3 = Average level of confidence 2 = Low level of confidence 1 = No level of confidence

	5	4	3	2	1
Assess your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.	Assess your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 5	Assess your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 4	Assess your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 3	Assess your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 2	Assess your ability to review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 1

As a result of participating in this activity, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	0
Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia.	Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia. - 5	Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia. - 4	Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia. - 3	Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia. - 2	Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia. - 1	Discuss the rationale for new targeted diagnostic and therapeutic strategies for lymphoma, myeloma and leukemia. - 0
Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options.	Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 5	Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 4	Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 3	Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 2	Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 1	Review the role and timing of hematopoietic cell transplantation and potential combinations of immunotherapeutic treatment options. - 0

How satisfied or dissatisfied were you with the Speaker's effectiveness in addressing the learning objectives? *

Scoring Key: 5=Strongly satisfied 4= Somewhat satisfied 3=Neither satisfied nor dissatisfied 2= Somewhat dissatisfied 1=Strongly dissatisfied NA= Not Applicable

	5	4	3	2	1	NA
Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology	Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology - 5	Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology - 4	Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology - 3	Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology - 2	Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology - 1	Marcel van den Brink, M.D., Ph.D. - The Role of Intestinal Microbiome in Hematopoietic Stem Cell Transplantation and Immuno-oncology - NA
Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation	Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation - 5	Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation - 4	Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation - 3	Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation - 2	Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation - 1	Robert Soiffer, M.D. - The Impact of CAR T-Cell Therapy on Hematopoietic Stem Cell Transplantation - NA
Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies	Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies - 5	Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies - 4	Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies - 3	Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies - 2	Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies - 1	Michel Sadelain, M.D., Ph.D. - Keynote Address - Next Steps in CAR T-cell Therapies - NA
Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat”	Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat” - 5	Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat” - 4	Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat” - 3	Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat” - 2	Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat” - 1	Robert Sackstein M.D., Ph.D. - Optimizing CAR Cell-based Immunotherapy by Targeting the Cancer Cell “Sugar-Coat” - NA
Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML	Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML - 5	Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML - 4	Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML - 3	Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML - 2	Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML - 1	Siddhartha Mukherjee, M.D. - Novel Approaches of CAR T-cell Therapies for AML - NA
Paul Lin, M.D. - Do CARs Always Have to Be T-Cells	Paul Lin, M.D. - Do CARs Always Have to Be T-Cells - 5	Paul Lin, M.D. - Do CARs Always Have to Be T-Cells - 4	Paul Lin, M.D. - Do CARs Always Have to Be T-Cells - 3	Paul Lin, M.D. - Do CARs Always Have to Be T-Cells - 2	Paul Lin, M.D. - Do CARs Always Have to Be T-Cells - 1	Paul Lin, M.D. - Do CARs Always Have to Be T-Cells - NA

Was this course fair, balanced and without commercial bias? *

Yes

If you checked "No,” please explain why: *

As a result of what was discussed at this activity what do you intend to do differently? Identify at least two learnings that could be incorporated into your practice *

What are the potential barriers or obstacles that might prevent you from implementing new strategies you learned at this activity? *

Comments

Name

Leave this field blank

You are here

Miami Cancer Institute Immunotherapies Evaluation - Day 2